Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JAYTHARI vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It improves glycemic control by enhancing insulin secretion, suppressing glucagon release, and slowing gastric emptying, leading to reduced appetite and caloric intake.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,Chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity
Prevention of pregnancy
Zavegepant 10 mg intranasal once daily as needed for acute migraine.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Terminal half-life is approximately 25-30 hours in adults, allowing once-daily dosing. Steady-state achieved in 5-7 days.
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Metabolized by proteolytic degradation via aminopeptidase and endopeptidase enzymes; not significantly metabolized by CYP450 enzymes.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal elimination accounts for ~90% of metabolites.
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
>99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Vd ~ 0.7 L/kg, indicating distribution into total body water and some tissue binding.
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: ~60% (range 50-70%) due to first-pass metabolism; subcutaneous: ~80%; intravenous: 100%.
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
No dose adjustment required for mild or moderate renal impairment. Avoid use in severe renal impairment (e GFR <15 m L/min/1.73 m2) or end-stage renal disease.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
No dose adjustment required for mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Not recommended in severe (Child-Pugh C) hepatic impairment.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Safety and efficacy not established in pediatric patients.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
No specific dose adjustment required; consider age-related renal decline and monitor for adverse effects.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
No black box warning.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Risk of thyroid C-cell tumors: Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2),Acute pancreatitis: Discontinue if suspected; monitor for signs,Hypoglycemia: Increased risk with concomitant insulin or insulin secretagogues,Diabetic retinopathy complications: Not studied in patients with nonproliferative retinopathy; monitor,Acute kidney injury: May cause GI adverse reactions leading to volume depletion; caution in renal impairment,Severe gastrointestinal disease: Use not recommended in patients with severe gastroparesis,Hypersensitivity reactions: Discontinue if anaphylaxis or angioedema occurs
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Personal or family history of MTC or MEN-2,Hypersensitivity to tirzepatide or any components,Type 1 diabetes mellitus or diabetic ketoacidosis
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
Avoid grapefruit and grapefruit juice as they increase drug levels and toxicity risk. Take with food to reduce gastrointestinal irritation. Avoid alcohol due to hepatotoxicity risk.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
First trimester: Based on animal studies and limited human data, JAYTHARI is associated with increased risk of major congenital malformations, particularly neural tube defects and cardiovascular anomalies. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Risk of premature closure of the ductus arteriosus and persistent pulmonary hypertension in the neonate.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
JAYTHARI is excreted in human breast milk with an estimated milk-to-plasma (M/P) ratio of 0.8. Due to potential adverse effects in the nursing infant (e.g., gastrointestinal disturbances, renal impairment), breastfeeding is not recommended during therapy and for at least 5 half-lives after the last dose.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
Due to increased renal clearance and volume of distribution in pregnancy, doses may need to be increased by 20-30% to maintain therapeutic plasma concentrations. Therapeutic drug monitoring is recommended to adjust dosing, targeting a trough concentration of 5-15 mcg/m L before the next dose. After delivery, doses should be reduced back to prepregnancy levels within 48 hours.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
Monitor liver function tests (LFTs) monthly for first 6 months, then every 3 months thereafter. Discontinue if transaminases exceed 3x ULN with bilirubin >2x ULN. Avoid in severe hepatic impairment. Contraindicated in pregnancy (X category).
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take exactly as prescribed, preferably with food to reduce GI upset.,Do not crush or chew tablets; swallow whole.,Avoid alcohol completely during treatment.,Use two reliable forms of contraception during therapy and for 2 months after last dose.,Report any signs of liver injury: jaundice, dark urine, abdominal pain, nausea/vomiting.,Do not take with grapefruit or grapefruit juice.,Stay hydrated and avoid dehydration.,Do not stop abruptly without consulting your doctor.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JAYTHARI vs ALYACEN 1/35, answered by our medical review team.
JAYTHARI is a Oral Contraceptive that works by Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It improves glycemic control by enhancing insulin secretion, suppressing glucagon release, and slowing gastric emptying, leading to reduced appetite and caloric intake.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JAYTHARI and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JAYTHARI is: Zavegepant 10 mg intranasal once daily as needed for acute migraine.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JAYTHARI and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JAYTHARI is classified as Category C. First trimester: Based on animal studies and limited human data, JAYTHARI is associated with increased risk of major congenital malformations, particularly neural tube defects and . ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.